Highlights
- •Diet interventions may be effective as self-management strategy in women with endometriosis
- •Nutrients with anti-inflammatory properties may suppress endometriosis symptoms
Abstract
Keywords
Introduction
- Simoens S.
- Dunselman G.
- Dirksen C.
- Hummelshoj L.
- Bokor A.
- Brandes I.
- Brodszky V.
- Canis M.
- Colombo G.L.
- DeLeire T.
- Falcone T.
- Graham B.
- Halis G.
- Horne A.
- Kanj O.
- Kjer J.J.
- Kristensen J.
- Lebovic D.
- Mueller M.
- Vigano P.
- Wullschleger M.
- D'Hooghe T.
Materials and methods
Eligibility criteria
Information sources
Search strategy
Study selection
Data extraction
Author/date, number of patients | Study design / type of study | Age (years) | Type of endometriosis | Dietary component | Dosage / intervention / duration | End-point of study | Result | P-value | Quality of evidence (GRADE) |
Vitamin D | |||||||||
Ailawadi et al., 2004 n = 10 | Phase 2 open-label non-randomized proof of concept study | 22–45 | Moderate to severe endometriosis scored with ASRM criteria | Letrozole; norethindrone acetate; calcium citrate, vitamin D | Dosage and intervention: 2.5 mg letrozole; 2.5 mg norethindrone acetate; 1250 mg calcium citrate; 800 IU vitamin D Duration: 6 months | ASRM score, pain score | Six months after treatment: lower ASRM score and lower pain score | ASRM: P = 0.0013 Pain: P < 0.001 | Very low |
Almassinokiani et al., 2016 n = 39 | Randomized double-blind clinical trial | 15–40 | Minimal to severe endometriosis | Vitamin D3 | Dosage: 50,000 IU vitamin D3 weekly Intervention: vitamin D3 Duration: 12 weeks | VAS score | No difference in VAS score 4 weeks after end of study between intervention and control group | Pelvic pain after intervention: P = 0.24 Dysmenorrhoea after intervention: P = 0.45 | Low |
Fatty acids | |||||||||
Indraccolo and Barbieri, 2010 )n = 4 | Prospective clinical study | 1 = 25, 2 = 27, 3 = 40, 4 = 45 | 1 = uterus, left uterosacral ligament 2 = ovarian, uterosacral ligaments 3 = bladder, uterosacral ligaments 4 = ovarian, rectovaginal septum | Palmitoylethanolamide and polydatin | Dosage and intervention: palmitoylethanolamide 400 mg Polydatin 40 mg, twice a day Duration: 3 months | VAS (for chronic pelvic pain, dysmenorrhoea, deep dyspareunia, dyschezia and dysuria) Use of analgesics | Pain scores chronic pelvic pain and dyspareunia decreased after 1 and 3 months No significant difference in dysmenorrhoea, dyschezia, dysuria Reduction in use of analgesics after 1, 2 and 3 months | Pain score chronic pelvic pain: P < 0.0069 after 1 month, no significant further decrease after 2 and 3 months Dyspareunia: P < 0.0132 after 1 month, no significant further decrease after 2 and 3 months Use of analgesics: P < 0.0176 after 1 month, no significant further decrease after 2 and 3 months | Very low |
Cobellis et al., 2011
Effectiveness of the association micronized N-Palmitoylethanolamine (PEA)-transpolydatin in the treatment of chronic pelvic pain related to endometriosis after laparoscopic assessment: a pilot study. Eur. J. Obstet. Gynecol. Reprod. Biol. 2011; 158: 82-86 n = 61 | Randomized double-blind parallel-group placebo-controlled clinical study | 24–61 | ASRM stage I and II | N-palmitoylethanolamine and transpolydatin | Dosage and intervention: Group A: palmitoylethanolamine + transpolydatin 400 mg + 40 mg twice a day Group B: placebo tablet; unclear how many tablets/day Group C: celecoxib, 200 mg twice a day, 7 days Duration: 3 months | VAS (for pelvic pain, dyspareunia and dysmenorrhoea) | VAS score lower in N-palmitoylethanolamine and transpolydatin compared with placebo. VAS score lower in celecoxib compared with N-palmitoylethanolamine and transpolydatin | P < 0.001 P < 0.001 | Low |
Giugliano et al., 2013 n = 47 | Prospective clinical study | 24–45 | Ovarian endometriosis and rectovaginal endometriosis | N-palmitoylethanolamine and transpolydatin | Dosage and intervention: palmitoylethanolamine 400 mg + transpolydatin 40 mg, twice a day Duration: 3 months | VAS (for chronic pelvic pain, dysmenorrhea, dyspareunia and dyschezia | Measurement at t = 0 (beginning treatment), after 30, 60 and 90 days After 30 days: lower VAS | P < 0.0001 after 30 days for chronic pelvic pain, dysmenorrhoea, dyspareunia P < 0.001 after 30 days for dyschezia | Very low |
De Leo et al., 2019 n = 60 | Prospective multicentre clinical study | 20–39 | Ovarian endometriosis | Alpha-lipoic acid, palmitoiethanolamide (PEA), myrrh | Dosage and intervention: 400 mg alpha-lipoic acid, 300 mg PEA, 100 mg myrrh, two tablets a day Duration: 6 months | VAS for dysmenorrhea, pelvic pain and dyspareunia at start and after 3 and 6 months Volume of endometrial ovarian cyst at start, after 3 and 6 months with ultrasound assessment | Chronic pelvic pain and dysmenorrhoea: after 3 and after 6 months significantly lower than at start Dyspareunia after 6 months significantly lower than at start Cyst volume: not changed after 3 and 6 months | Chronic pelvic pain and dysmenorrhoea: P < 0.05 after 3 and after 6 months Dyspareunia: P < 0.05 after 6 months | Very low |
Antioxidants | |||||||||
Morales-Prieto et al., 2018 n = 8 | Case series | 34–51 | Surgically confirmed endometriosis | 3,3-diindolylmethane (DIM); dienogest (DNG) | Dosage and intervention: Group 1: 2 mg DNG once per day and 100 mg DIM three times per day Group 2: 2 mg DNG once per day Duration: 3 months | Endometriosis-associated pelvic pain (EAPP) using VAS after 1, 2 and 3 months Bleeding pattern after 1, 2 and 3 months | Pain: EAPP was lower in DNG group compared with DNG-DIM group at start of study. At the end of study, EAPP was significantly decreased in both groups. EAPP was higher in DNG group than in DNG-DIM group Bleeding pattern: fewer bleeding days and less heavy bleeding in DNG-DIM group as compared with DNG group | Pain: EAPP DNG-DIM vs DNG group P < 0.05 Bleeding pattern: number of days of bleeding DNG-DIM vs DNG alone P < 0.05 | Very low |
Gluten and soy | |||||||||
Chandrareddy et al., 2008 n = 2 | Case report | 35, 43 | 1. Ovarian 2. Not described | No soy | Soy-free diet | Not defined | 1. After 3 months without soy: free of dysmenorrhoea, abdominal pain subsided 2. Improvement of symptoms, became pregnant | n/a | Very low |
Caserta et al., 2014 n = 1 | Case report | 34 | Ovarian endometriosis | No gluten | Gluten-free diet | Not defined | Pregnancy | n/a | Very low |
More than one dietary intervention | |||||||||
Sesti et al., 2007
Hormonal suppression treatment or dietary therapy versus placebo in the control of painful symptoms after conservative surgery for endometriosis stage III-IV. A randomized comparative trial. Fertil. Steril. 2007; 88: 1541-1547 n = 222 | Randomized comparative trial | Reproductive age up to 40 | rAFS III–IV | Vitamin B6, A, C, E; Ca, Mg, Se, Zn, Fe; VSL3 lactic ferments (Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus bulgaricus, Streptococcus thermophilus); omega-3 and omega-6 fatty acids | Dosage and intervention: surgical intervention: conservative surgery. Post-surgical treatment: -placebo (n = 110) -GnRH analogue 3.75 mg/month (n = 39) -OC continuously (n = 38) -dietary intervention (n = 35) A different dietary protocol was assigned according to body mass index, physical activity, and job of each woman Duration: 6 months | Pain (VAS score) and QoL (SF36) 18 months after surgery | 18 months after surgery: pain and QoL equal in hormonal treatment group and dietary group, but less pain and better QoL in both treatment groups compared with placebo group | Pain scores: P < 0.001 | Low |
Author/date, number of patients | Study design / type of study | Age (years) | Type of endometriosis | Dietary component | Dosage / intervention / duration | End-point of study | Result | P-value | Quality of evidence (GRADE) |
Sesti et al., 2009
Recurrence rate of endometrioma after laparoscopic cystectomy: a comparative randomized trial between post-operative hormonal suppression treatment or dietary therapy vs. placebo. Eur. J. Obstet. Gynecol. Reprod. Biol. 2009; 147: 72-77 n = 240 | Randomized comparative trial | Reproductive age up to 40 | Endometrioma | Vitamin B6, A, C, E; Ca, Mg, Se, Zn, Fe; VSL3 lactic ferments (Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus bulgaricus, Streptococcus thermophilus); omega-3 and omega-6 fatty acids | Dosage and intervention: surgical intervention: cystectomy and adhesiolysis Post-surgical treatment: -placebo (n = 60) -GnRH analogue 3.75 mg/month (n = 58) -OC continuously (n = 60) -dietary intervention (n = 62) A different dietary protocol was assigned according to body mass index, physical activity, and job of each woman Duration: 6 months | Recurrence of endometrioma 18 months after surgery | No differences in recurrence between study groups | P = 0.544 | Low |
Moore et al., 2017 n = 59 | Retrospective study | 28 (16–65) | Not described. (Patients had surgically confirmed endometriosis and IBS) | Low FODMAP | Dosage: no FODMAP Intervention: low FODMAP diet Duration: effect was reported after 4 weeks | Response to low FODMAP, defined as >50% improvement of symptoms in women with endometriosis and IBS, compared with response to low FODMAP in patients with IBS alone | Adherence to low FODMAP n = 55 (93%), response to low FODMAP n = 43 (72%) | Response: P = 0.001 | Very low |
Assessment of risk of bias
Study | Start | 1. Limitation in study design | 2. Imprecision | 3. Inconsistency | 4. Indirectness | 5. Publication bias | Factors increasing the quality of the study | Conclusion |
---|---|---|---|---|---|---|---|---|
Vitamin D | ||||||||
Ailawadi, 2004 | Low (Phase 2 open-label non-randomized proof of concept study) | Serious: lack of control group | Serious: small study group | No | Serious: very heterogeneous intervention: combination of hormonal treatment and vitamin D, unclear what causes the effect | No | No | Very low quality (downgrade 3 levels due to 1, 2, 4) |
Almassinokiani, 2016 | High (RCT) | No | Serious: small and heterogeneous group of patients | No | No | Serious: negative study results, risk of journal selection | No | Low quality (downgrade two levels due to 2) |
Fatty acids | ||||||||
Indraccolo, 2010 | Low (observational studies) | Serious: case series | Not serious | No | No | No | No | Very low quality (downgrade 1 level due to 1) |
Cobellis, 2011 | High (RCT) | Serious: lack of blinding | No | Serious: heterogeneity of results: in two out of three groups, patients are very satisfied to very unsatisfied within the same study group | Not serious | No | No | Low quality (downgrade two levels due to 1,3) |
Giugliano, 2013 | Low (prospective clinical study) | Serious: lack of control group | No | No | Not serious | No | No | Very low quality (downgrade one level due to 1) |
De Leo et al., 2019 | Low (open-label prospective clinical study) | Serious: lack of control group | Serious: small study group | No | No | No | No | Very low quality (downgrade 2 levels due to 1, 2) |
Antioxidants | ||||||||
Morales-Prieto, 2018 | Low (observational studies) | Serious: case series; lack of group of cases using DIM alone | Not serious | No | Serious: use of surrogacy outcome: bleeding pattern; and lack of cases using DIM alone | No | No | Very low quality (downgrade 2 levels due to 1, 4) |
Gluten and soy | ||||||||
Chandrareddy, 2008 | Low quality (observational study) | Serious: case report | No | No | Serious: small and different characteristics of the cases | No | No | Very low quality |
Caserta, 2014 | Low quality (observational study) | Serious: case report | No | Serious: unclear what disease caused effect of intervention | Serious: small research group, unclear follow-up | No | No | Very low quality |
More than one dietary intervention | ||||||||
Sesti, 2007 | High (RCT) | No | No | No | Very serious: heterogeneous diet intervention and heterogeneous surgical interventions, unclear what diet intervention or which surgical therapy causes which effect | No | No | Low quality (downgrade two levels due to 4) |
Sesti, 2009 | High (RCT) | No | No | No | Very serious: heterogeneous diet intervention, unclear what intervention causes which effect; type of endometriosis varies from ASRM I to IV despite design that says ovarian endometrioma | No | No | Low quality (downgrade two levels due to 4) |
Moore, 2016 | Low quality (observational study) | No | No | No | Serious: large difference in study population and number of patients in each group | Serious: possible over-interpretation of positive results of diet in subgroup of original study population | No | Very low quality (downgrade two levels due to combination of 4 and 5) |
Data synthesis and analysis
Results
Study selection
- Cobellis L.
- Castaldi M.A.
- Giordano V.
- Trabucco E.
- De Franciscis P.
- Torella M.
- Colacurci N.
- Sesti F.
- Pietropolli A.
- Capozzolo T.
- Broccoli P.
- Pierangeli S.
- Bollea M.R.
- Piccione E.
- Sesti F.
- Capozzolo T.
- Pietropolli A.
- Marziali M.
- Bollea M.R.
- Piccione E.

Study characteristics
- Cobellis L.
- Castaldi M.A.
- Giordano V.
- Trabucco E.
- De Franciscis P.
- Torella M.
- Colacurci N.
- Sesti F.
- Pietropolli A.
- Capozzolo T.
- Broccoli P.
- Pierangeli S.
- Bollea M.R.
- Piccione E.
Risk of bias of included studies
Synthesis of results
Effective nutrients
Vitamin D
Fatty acids
- Cobellis L.
- Castaldi M.A.
- Giordano V.
- Trabucco E.
- De Franciscis P.
- Torella M.
- Colacurci N.
- Cobellis L.
- Castaldi M.A.
- Giordano V.
- Trabucco E.
- De Franciscis P.
- Torella M.
- Colacurci N.
Antioxidants
Gluten
Soy
Combination of nutrients
- Sesti F.
- Pietropolli A.
- Capozzolo T.
- Broccoli P.
- Pierangeli S.
- Bollea M.R.
- Piccione E.
- Sesti F.
- Capozzolo T.
- Pietropolli A.
- Marziali M.
- Bollea M.R.
- Piccione E.
- Sesti F.
- Pietropolli A.
- Capozzolo T.
- Broccoli P.
- Pierangeli S.
- Bollea M.R.
- Piccione E.
- Sesti F.
- Capozzolo T.
- Pietropolli A.
- Marziali M.
- Bollea M.R.
- Piccione E.
Discussion
- Cobellis L.
- Castaldi M.A.
- Giordano V.
- Trabucco E.
- De Franciscis P.
- Torella M.
- Colacurci N.
- Cobellis L.
- Castaldi M.A.
- Giordano V.
- Trabucco E.
- De Franciscis P.
- Torella M.
- Colacurci N.
Dutch Health Council (Gezondheidsraad)., 2015. Richtlijnen goede voeding.https://www.gezondheidsraad.nl/documenten/adviezen/2015/11/04/richtlijnen-goede-voeding-2015. Consulted at 25–8-2019.
Dutch Health Council (Gezondheidsraad)., 2018. Voedingsnormen voor vitamines en mineralen voor volwassenen.https://www.gezondheidsraad.nl/documenten/adviezen/2018/09/18/gezondheidsraad-herziet-voedingsnormen-voor-volwassenen. Consulted at 25–8-2019.
Nutrient | Nutrient-rich foods | Recommended amount for women |
---|---|---|
Fatty acids | ||
Palmitoylethanolamide (PEA) | Eggs, peanuts | No recommended daily amount |
Omega-3 fatty acids | Linolenic acid: oils (flax seed, canola, walnut, wheatgerm, soybean), nuts and seeds (butternuts, flax seeds, walnuts, soybean kernels) Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA): human milk, fatty fish | 1% of adequate energy intake |
Omega-6 fatty acids | Linoleic acid: vegetable oils (corn, sunflower, safflower, soybean, cottonseed), poultry fat, nuts (pine nuts, walnuts), seeds (sesame, sunflower and pumpkin) Arachidonic acid: meats, poultry, eggs, mayonnaise, margarine | 2% of adequate energy intake |
Vitamins, minerals and antioxidants | ||
Vitamin A | Cheese, cream, butter, fortified margarine, butter, eggs, liver, dark leafy greens, deep orange fruits (apricots, cantaloupe), vegetables (sweet potatoes, pumpkin, squash, carrots) | 680 µg mg/day |
Vitamin B6 | Meat (chicken breast), fish, poultry, potatoes and other starchy vegetables, legumes, non-citrus fruits (banana, watermelon) | 1.5 micrograms/day |
Vitamin C | (Citrus) fruits, cabbage-type vegetables (Brussels sprouts, cauliflower), dark green vegetables (bell pepper, broccoli), cantaloupe, strawberries, lettuce, tomatoes, potatoes, papayas, mangoes, kiwi | 75 µg/day |
Vitamin D | Fortified foods such as milk, margarine, butter. Egg yolks, liver, fatty fish, veal | 10 µg/day (AI) |
Vitamin E | Polyunsaturated plant oils, leafy green vegetables, wheatgerm, wholegrains, liver, egg yolks, nuts, seeds, avocado | 11 mg/day |
Calcium | Milk, cheese, yoghurt, small fish with bones (sardines), tofu, greens (Chinese cabbage, broccoli, kale) | Age 25–49 years: 950 mg/day |
Iron | Red meat, eggs, fish, shellfish, poultry, dried fruits, tomatoes | Pre-menopausal 16 mg/day Post-menopausal 11 mg/day |
Magnesium | Nuts (cashews), seeds, avocado, dried fruits, cacao powder, wholegrains | 350 mg/day |
Selenium | Seafood, meat, wholegrains, fruits, vegetables | 70 µg/day |
Zinc | Red meat, shellfish, wholegrains | 7 mg/day |
Indole-3-carbinol (I3C) | Cruciferous vegetables such as cabbage, Brussels sprouts, broccoli | No recommended daily amount |
Polydatin | Grapes, wine, hop cones and pellets, beer, cocoa containing product and chocolate | No recommended daily amount |
Lactobacilli | Yoghurt, kefir | No recommended daily amount |
Type of study | Study question | Goal |
---|---|---|
Descriptive exploratory study | Do women with endometriosis have a healthy diet according to WHO criteria? What dietary intervention is used by women with endometriosis and what is its perceived effectiveness regarding endometriosis related symptoms? | Finding out whether a healthy diet according to WHO criteria, or changing diet itself is effective against endometriosis related symptoms |
Prospective randomized controlled trial | What is the effect on endometriosis-related symptoms of adding or omitting specific (combinations of) nutrients to the diet of women with endometriosis, compared with a normal diet? | Finding out whether adding or omitting single nutrients or a combination of nutrients is effective against endometriosis-related symptoms |
Laboratory study | What amount of effective nutrients is present in specific food products? | Finding out which specific food products should be advised in an endometriosis diet and in which amounts per day |
References
- Treatment of endometriosis and chronic pelvic pain with letrozole and norethindrone acetate: a pilot study.Fertil. Steril. 2004; 81: 290-296
- Effects of Vitamin D on Endometriosis-Related Pain: A Double-Blind Clinical Trial.Med. Sci. Monit. 2016; 22: 4960-4966
- Self-management strategies amongst Australian women with endometriosis: a national online survey.B.M.C. Complement Altern. Med. 2019; 19: 17
- Time elapsed from onset of symptoms to diagnosis of endometriosis in a cohort study of Brazilian women.Hum. Reprod. 2003; 18: 756-759
- Indole-3-carbinol is a negative regulator of estrogen.J. Nutr. 2003; 133: 2470S-2475S
- What's the delay? A qualitative study of women's experiences of reaching a diagnosis of endometriosis.Fertil. Steril. 2006; 86: 1296-1301
- Celiac disease and endometriosis: an insidious and worrisome association hard to diagnose: a case report.Clin. Exp. Obstet. Gynecol. 2014; 41: 346-348
- Adverse effects of phytoestrogens on reproductive health: a report of three cases.Complement Ther. Clin. Pract. 2008; 14: 132-135
- Effectiveness of the association micronized N-Palmitoylethanolamine (PEA)-transpolydatin in the treatment of chronic pelvic pain related to endometriosis after laparoscopic assessment: a pilot study.Eur. J. Obstet. Gynecol. Reprod. Biol. 2011; 158: 82-86
- The significant effect of endometriosis on physical, mental and social wellbeing: results from an international cross–sectional survey.Hum. Reprod. 2013; 28: 2677-2685
- Role of a natural integrator based on lipoic acid, palmitoiletanolamide and myrrh in the treatment of chronic pelvic pain and endometriosis.Minerva Ginecol. 2019; 71: 191-195
- The dietary intake of wheat and other cereal grains and their role in inflammation.Nutrients. 2013; 5: 771-787
- ESHRE guideline: management of women with endometriosis.Hum. Reprod. 2014; 29: 400-412
Dutch Health Council (Gezondheidsraad)., 2015. Richtlijnen goede voeding.https://www.gezondheidsraad.nl/documenten/adviezen/2015/11/04/richtlijnen-goede-voeding-2015. Consulted at 25–8-2019.
Dutch Health Council (Gezondheidsraad)., 2018. Voedingsnormen voor vitamines en mineralen voor volwassenen.https://www.gezondheidsraad.nl/documenten/adviezen/2018/09/18/gezondheidsraad-herziet-voedingsnormen-voor-volwassenen. Consulted at 25–8-2019.
- Clinical practice. Endometriosis.N. Engl. J. Med. 2010; 362: 2389-2398
- The adjuvant use of N-palmitoylethanolamine and transpolydatin in the treatment of endometriotic pain.Eur. J. Obstet. Gynecol. Reprod. Biol. 2013; 168: 209-213
- GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables.J. Clin. Epidemiol. 2011; 64: 383-394
- Delay in the diagnosis of endometriosis: a survey of women from the USA and the UK.Hum. Reprod. 1996; 11: 878-880
- Retrograde menstruation in healthy women and in patients with endometriosis.Obstet. Gynecol. 1984; 64: 151-154
- Dairy-food, calcium, magnesium, and vitamin D intake and endometriosis: a prospective cohort study.Am. J. Epidemiol. 2013; 177: 420-430
- Diagnostic delay for endometriosis in Austria and Germany: causes and possible consequences.Hum. Reprod. 2012; 7: 3412-3416
- Effect of palmitoylethanolamide-polydatin combination on chronic pelvic pain associated with endometriosis: preliminary observations.Eur. J. Obstet. Gynecol. Reprod. Biol. 2010; 150: 76-79
- Inflammation and endometriosis.Front. Biosci. 2016; 21: 941-948
- The intestinal barrier and its regulation by neuroimmune factors.Neurogastroenterol. Motil. 2010; 22: 718-733
- Prevention of the recurrence of symptom and lesions after conservative surgery for endometriosis.Fertil. Steril. 2015; 104: 793-801
- The palmitoylethanolamide family: a new class of anti-inflammatory agents?.Curr. Med. Chem. 2002; 9: 663-674
- Cytostatic effects of 3,3′-diindolylmethane in human endometrial cancer cells result from an estrogen receptor-mediated increase in transforming growth factor-alpha expression.Carcinogenesis. 2001; 22: 1809-1817
- Endometriosis in patients with irritable bowel syndrome: Specific symptomatic and demographic profile, and response to the low FODMAP diet.Aust. N. Z. J. Obstet. Gynaecol. 2017; 57: 201-205
- Comparison of dienogest effects upon 3,3’-diindolylmethane supplementation in models of endometriosis and clinical cases.Reprod. Biol. 2018; 18: 252-258
- Shedding new light on female fertility: The role of vitamin D.Rev. Endocr. Metab. Disord. 2017; 18: 273-283
- Self-management in condition-specific health: a systematic review of the evidence among women diagnosed with endometriosis.B.M.C. Womens Health. 2019; 19: 80
- Herbal and dietary therapies for primary and secondary dysmenorrhea (review).Cochrane database Syst. Rev. 2001; 2CD002124
- Peritoneal endometriosis due to menstrual dissemination of endometrial tissue into the peritoneal cavity.Am. J. Obstet. Gynecol. 1927; 14: 422-469
- Vitamin D in endometriosis: a causative or confounding factor?.Metabolism. 2014; 63: 32-41
- Endometriosis and its coexistence with irritable bowel syndrome and pelvic inflammatory disease: findings from a national case–control study–Part 2.BJOG. 2008; 115: 1392-1396
- Hormonal suppression treatment or dietary therapy versus placebo in the control of painful symptoms after conservative surgery for endometriosis stage III-IV. A randomized comparative trial.Fertil. Steril. 2007; 88: 1541-1547
- Recurrence rate of endometrioma after laparoscopic cystectomy: a comparative randomized trial between post-operative hormonal suppression treatment or dietary therapy vs. placebo.Eur. J. Obstet. Gynecol. Reprod. Biol. 2009; 147: 72-77
- Eating ourselves to death (and despair): The contribution of adiposity and inflammation to depression.Prog. Neurobiol. 2010; 91: 275-299
- The burden of endometriosis: costs and quality of life of women with endometriosis and treated in referral centres.Hum. Reprod. 2012; 27: 1292-1299
- Recent advances in chemistry, therapeutic properties and sources of polydatin.Phytochemistry Reviews. 2018; 1: 33
- Gynaecologists’ view on diagnostic delay and care performance in endometriosis in the Netherlands.Reprod. Biomed. Online. 2018; 37: 761-768
- The effect of surgery for symptomatic endometriosis: the other side of the story.Hum. Reprod. Update. 2009; 15: 177-188
Whitney, E.N., Rolfes, S.R., 2011. Understanding nutrition, first ed. Belmont, California.
- Endometriosis: disease pathophysiology and the role of prostaglandins.Expert. Rev. Mol. Med. 2007; 16: 1-20
Biography
